SEC Form 4 · accession 0001209191-15-059210
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Farah Champsi
Director
Period of report
Jun 30, 2015
Accepted (ET)
Jul 2, 2015 · 7:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jun 30, 2015 | S | 191,798 | $61.22 | D | 2,234,261 | I | See Footnote |
| Common StockF4,F3 | Jun 30, 2015 | S | 113,047 | $62.14 | D | 2,121,214 | I | See Footnote |
| Common StockF5,F3 | Jun 30, 2015 | S | 358,757 | $63.01 | D | 1,762,457 | I | See Footnote |
| Common StockF3 | Jun 30, 2015 | S | 500 | $63.82 | D | 1,761,957 | I | See Footnote |
| Common StockF6 | holding | — | — | — | 19,666 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.70 to $61.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F2Reflects the disposition by Alta Partners VIII, L.P. ("APVIII") of 500,000 shares of the Issuer's common stock in a pro-rata distribution to its limited partners on June 30, 2015.
- F3The securities are held of record by APVIII. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. The reporting person is a managing director of APMVIII and exercises shared voting and investment power with respect to the shares owned by APVIII. The reporting person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.71 to $62.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.715 to $63.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F6Includes 19,666 shares received in a pro-rata distribution from APVIII. In prior reports, the reporting person reported beneficial ownership of all shares of the Issuer's common stock held by APVIII.